Susana T Valente

Summary

Affiliation: The Scripps Research Institute
Country: USA

Publications

  1. pmc HIV-1 Capsid Inhibitors as Antiretroviral Agents
    Suzie Thenin-Houssier
    Department Immunology and Microbial Sciences, The Scripps Research Institute, 130 Scripps Way, 3C1, Jupiter, FL 33458, USA
    Curr HIV Res 14:270-82. 2016
  2. pmc Didehydro-cortistatin A inhibits HIV-1 Tat mediated neuroinflammation and prevents potentiation of cocaine reward in Tat transgenic mice
    Sonia Mediouni
    Department of Infectious Diseases, The Scripps Research Institute, 130 Scripps Way, 3C1, Jupiter, FL 33458, USA
    Curr HIV Res 13:64-79. 2015
  3. pmc HIV-1 mRNA 3' end processing is distinctively regulated by eIF3f, CDK11, and splice factor 9G8
    Susana T Valente
    Howard Hughes Medical Institute, College of Physicians and Surgeons, Columbia University, HHSC 1310c, 701 West 168th Street, New York, NY 10032, USA
    Mol Cell 36:279-89. 2009
  4. pmc Inhibition of HIV-1 replication by eIF3f
    Susana T Valente
    Department of Biochemistry and Molecular Biophysics, Howard Hughes Medical Institute, College of Physicians and Surgeons, Columbia University, HHSC 1310c, 701 West 168th Street, New York, NY 10032, USA
    Proc Natl Acad Sci U S A 106:4071-8. 2009
  5. pmc Ebselen, a Small-Molecule Capsid Inhibitor of HIV-1 Replication
    Suzie Thenin-Houssier
    Department of Immunology and Microbial Sciences, The Scripps Research Institute, Jupiter, Florida, USA
    Antimicrob Agents Chemother 60:2195-208. 2016
  6. pmc An analog of the natural steroidal alkaloid cortistatin A potently suppresses Tat-dependent HIV transcription
    Guillaume Mousseau
    Department of Infectology, The Scripps Research Institute, Scripps Florida, Jupiter, 33458, USA
    Cell Host Microbe 12:97-108. 2012
  7. pmc Didehydro-Cortistatin A: a new player in HIV-therapy?
    Guillaume Mousseau
    a Department of Immunology and Microbial Science, The Scripps Research Institute, Jupiter, FL, USA
    Expert Rev Anti Infect Ther 14:145-8. 2016
  8. pmc The Tat Inhibitor Didehydro-Cortistatin A Prevents HIV-1 Reactivation from Latency
    Guillaume Mousseau
    Department of Immunology and Microbial Sciences, The Scripps Research Institute, Jupiter, Florida, USA
    MBio 6:e00465. 2015
  9. pmc Targeting HIV transcription: the quest for a functional cure
    Guillaume Mousseau
    Department of Infectious Diseases, The Scripps Research Institute, Jupiter, FL, 33458, USA
    Curr Top Microbiol Immunol 389:121-45. 2015
  10. ncbi request reprint Inhibition of HIV-1 gene expression by a fragment of hnRNP U
    Susana T Valente
    Howard Hughes Medical Institute, College of Physicians and Surgeons, Columbia University, HHSC 1310c, 701 West 168th Street, New York, New York 10032, USA
    Mol Cell 23:597-605. 2006

Collaborators

Detail Information

Publications12

  1. pmc HIV-1 Capsid Inhibitors as Antiretroviral Agents
    Suzie Thenin-Houssier
    Department Immunology and Microbial Sciences, The Scripps Research Institute, 130 Scripps Way, 3C1, Jupiter, FL 33458, USA
    Curr HIV Res 14:270-82. 2016
    ..Unfortunately, none of these molecules is currently used in the clinic...
  2. pmc Didehydro-cortistatin A inhibits HIV-1 Tat mediated neuroinflammation and prevents potentiation of cocaine reward in Tat transgenic mice
    Sonia Mediouni
    Department of Infectious Diseases, The Scripps Research Institute, 130 Scripps Way, 3C1, Jupiter, FL 33458, USA
    Curr HIV Res 13:64-79. 2015
    ..Our results suggest that adding a Tat inhibitor, such as dCA, to current antiretroviral therapy may reduce HIV-1-related neuropathogenesis. ..
  3. pmc HIV-1 mRNA 3' end processing is distinctively regulated by eIF3f, CDK11, and splice factor 9G8
    Susana T Valente
    Howard Hughes Medical Institute, College of Physicians and Surgeons, Columbia University, HHSC 1310c, 701 West 168th Street, New York, NY 10032, USA
    Mol Cell 36:279-89. 2009
    ..eIF3f affects HIV-1 3' end processing by modulating the sequence-specific recognition of the HIV-1 pre-mRNA by 9G8...
  4. pmc Inhibition of HIV-1 replication by eIF3f
    Susana T Valente
    Department of Biochemistry and Molecular Biophysics, Howard Hughes Medical Institute, College of Physicians and Surgeons, Columbia University, HHSC 1310c, 701 West 168th Street, New York, NY 10032, USA
    Proc Natl Acad Sci U S A 106:4071-8. 2009
    ..Our results suggest a role of eIF3f in mRNA maturation and that it can specifically interfere with the 3' end processing of HIV-1 mRNAs...
  5. pmc Ebselen, a Small-Molecule Capsid Inhibitor of HIV-1 Replication
    Suzie Thenin-Houssier
    Department of Immunology and Microbial Sciences, The Scripps Research Institute, Jupiter, Florida, USA
    Antimicrob Agents Chemother 60:2195-208. 2016
    ..This study reports the use of TR-FRET screening to successfully identify a novel capsid inhibitor, ebselen, validating HIV-1 capsid as a promising target for drug development. ..
  6. pmc An analog of the natural steroidal alkaloid cortistatin A potently suppresses Tat-dependent HIV transcription
    Guillaume Mousseau
    Department of Infectology, The Scripps Research Institute, Scripps Florida, Jupiter, 33458, USA
    Cell Host Microbe 12:97-108. 2012
    ..Thus, dCA defines a unique class of anti-HIV drugs that may inhibit viral production from stable reservoirs and reduce residual viremia during HAART...
  7. pmc Didehydro-Cortistatin A: a new player in HIV-therapy?
    Guillaume Mousseau
    a Department of Immunology and Microbial Science, The Scripps Research Institute, Jupiter, FL, USA
    Expert Rev Anti Infect Ther 14:145-8. 2016
    ..Here we discuss the use of Tat inhibitors to limit the latent reservoir to achieve a functional cure. ..
  8. pmc The Tat Inhibitor Didehydro-Cortistatin A Prevents HIV-1 Reactivation from Latency
    Guillaume Mousseau
    Department of Immunology and Microbial Sciences, The Scripps Research Institute, Jupiter, Florida, USA
    MBio 6:e00465. 2015
    ..Our results suggest that inclusion of a Tat inhibitor in current ART regimens may contribute to a functional HIV-1 cure by reducing low-level viremia and preventing viral reactivation from latent reservoirs...
  9. pmc Targeting HIV transcription: the quest for a functional cure
    Guillaume Mousseau
    Department of Infectious Diseases, The Scripps Research Institute, Jupiter, FL, 33458, USA
    Curr Top Microbiol Immunol 389:121-45. 2015
    ..Finally, we discuss the impact of extracellular Tat in HIV-associated neurocognitive disorders and cancers. ..
  10. ncbi request reprint Inhibition of HIV-1 gene expression by a fragment of hnRNP U
    Susana T Valente
    Howard Hughes Medical Institute, College of Physicians and Surgeons, Columbia University, HHSC 1310c, 701 West 168th Street, New York, New York 10032, USA
    Mol Cell 23:597-605. 2006
    ..The results suggest that HIV-1 requires machinery for the nuclear export of viral mRNAs that can be specifically blocked by an interfering gene...
  11. pmc Somatic cell genetic analyses to identify HIV-1 host restriction factors
    Susana T Valente
    Department of Biochemistry, Columbia University, Howard Hughes Medical Institute College of Physicians and Surgeons, New York NY, USA
    Methods Mol Biol 485:235-55. 2009
    ..Here we report the strategy and techniques to prepare a library and isolate HIV antiviral genes, using the identification of N-86-HnRNPU as an example...
  12. pmc Cell-Permeable Peptides Containing Cycloalanine Residues
    Hao Wu
    Department of Chemistry and Cancer Biology, The Scripps Research Institute, 130 Scripps Way, Jupiter, FL, 33458, USA
    Angew Chem Int Ed Engl 55:12637-42. 2016
    ..We demonstrate the utility of this chemistry in creating a cell-permeable derivative of a high-affinity HIV Rev protein-binding peptide. ..